What's Happening?
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, is set to participate in several conferences in September 2025. The company will present its investigational therapy, Haduvio, which targets chronic cough in patients with idiopathic pulmonary fibrosis and refractory chronic cough. Trevi's management, including CEO Jennifer Good, will attend the Wells Fargo Healthcare Conference, Cantor Global Healthcare Conference, Morgan Stanley Global Healthcare Conference, and the European Respiratory Society Congress. Haduvio has shown promising results in reducing cough frequency in clinical trials, offering potential relief for patients with chronic cough conditions.
AD
Why It's Important?
Chronic cough significantly impacts patients' quality of life, with no approved therapies currently available in the U.S. Trevi Therapeutics' development of Haduvio represents a potential breakthrough in treating this debilitating condition. Successful clinical trials and presentations at these conferences could attract investor interest and pave the way for regulatory approval, addressing a significant unmet medical need. The therapy's advancement could improve patient outcomes and reduce the social and economic burdens associated with chronic cough.
What's Next?
Trevi Therapeutics aims to continue its clinical trials and seek regulatory approval for Haduvio. The company's participation in these conferences may lead to increased visibility and potential partnerships, accelerating the path to commercialization. Stakeholders will be monitoring the results of ongoing studies and any strategic developments that may arise from these events.
